

Adaptimmune Therapeutics PLC  
Form 6-K  
July 20, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of July, 2015

Commission File Number: 001-37368

---

**ADAPTIMMUNE THERAPEUTICS PLC**

(Translation of registrant's name into English)

---

101 Park Drive, Milton Park  
Abingdon, Oxfordshire OX14 4RY  
United Kingdom

Edgar Filing: Adaptimmune Therapeutics PLC - Form 6-K

(Address of principal executive offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

---

**Other Events**

On July 20, 2015, Adaptimmune Therapeutics plc (the Company ) issued a press release announcing that data from its phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in *Nature Medicine*. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

**Exhibits**

99.1 Press release dated July 20, 2015

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Adaptimmune Therapeutics plc**

By:	/s/ Margaret Henry
Name:	Margaret Henry
Title:	Corporate Secretary

Date: July 20, 2015